ArticleJournal of clinical practice and research2025
Impact of Oral Iron Therapy on Oxidative Stress and DNA Damage in Women of Reproductive Age.
Article in Journal of clinical practice and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Iron Metabolism in the Colorectal Tumor Microenvironment: Current Evidence and Clinical Implications.Diagnostics (Basel, Switzerland) · 2026Review
- Interplay of Total Antioxidant Capacity and Oxidative Stress Hydroperoxides with Circulating Biomarkers of Inflammation and Iron Status According to Oral Contraception Use.Antioxidants (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Iron deficiency anemia (IDA) is a condition that increases morbidity and mortality. This study investigated changes in oxidative stress, DNA damage, and hepcidin levels following therapy in individuals with IDA. Materials and Methods: The patient group consisted of 39 females diagnosed with IDA, and 36 age- and sex-matched controls were incorporated into our study (18-49 years). The patient group was treated with daily oral ferrous fumarate (304.2 mg, approximately 100 mg elemental iron) for one month. Measurements of total oxidant status (TOS), total antioxidant status (TAS), oxidative stress index (OSI), DNA damage (using the Comet assay), and hepcidin levels were conducted before and during therapy and compared between the patient and control groups. Results: Oxidative stress indicators and DNA damage assessed with the Comet assay were elevated in individuals with IDA (p=0.018) and decreased following treatment (p=0.002). TAS was reduced in individuals with IDA (p=0.02) but increased after treatment (p<0.001). Although TOS levels were elevated in individuals with IDA, the difference was not statistically significant (p=0.10); however, TOS levels decreased after treatment (p=0.02). Hepcidin levels were significantly lower in individuals with IDA (p<0.001) but increased during therapy (p<0.001). Conclusion: This study demonstrates that just one month of oral iron therapy can reversibly improve oxidative stress and DNA damage. Hepcidin plays a critical role in maintaining iron homeostasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.